236 related articles for article (PubMed ID: 36980828)
1. Cellular Transcriptomics of Carboplatin Resistance in a Metastatic Canine Osteosarcoma Cell Line.
Hodge MA; Miller T; Weinman MA; Wustefeld-Janssens B; Bracha S; Davis BW
Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980828
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
3. Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling.
Foley JM; Scholten DJ; Monks NR; Cherba D; Monsma DJ; Davidson P; Dylewski D; Dykema K; Winn ME; Steensma MR
J Transl Med; 2015 Apr; 13():110. PubMed ID: 25889105
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.
Zhu KP; Zhang CL; Shen GQ; Zhu ZS
Int J Clin Exp Pathol; 2015; 8(8):8754-73. PubMed ID: 26464619
[TBL] [Abstract][Full Text] [Related]
5. PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1.
Cheng C; Ding Q; Zhang Z; Wang S; Zhong B; Huang X; Shao Z
J Cell Mol Med; 2020 May; 24(9):5274-5289. PubMed ID: 32207235
[TBL] [Abstract][Full Text] [Related]
6. S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells.
Ding L; Wang C; Cui Y; Han X; Zhou Y; Bai J; Li R
Int J Oncol; 2018 Jun; 52(6):1841-1852. PubMed ID: 29620168
[TBL] [Abstract][Full Text] [Related]
7. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance.
Shahi MH; York D; Gandour-Edwards R; Withers SS; Holt R; Rebhun RB
PLoS One; 2015; 10(6):e0131006. PubMed ID: 26110620
[TBL] [Abstract][Full Text] [Related]
8. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
Xiao X; Wang W; Li Y; Yang D; Li X; Shen C; Liu Y; Ke X; Guo S; Guo Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):201. PubMed ID: 30153855
[TBL] [Abstract][Full Text] [Related]
9. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
10. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
Cancer Biomark; 2020; 28(2):231-246. PubMed ID: 32508321
[TBL] [Abstract][Full Text] [Related]
11. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
Poon AC; Inkol JM; Luu AK; Mutsaers AJ
J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
[TBL] [Abstract][Full Text] [Related]
12. LncRNA EBLN3P attributes methotrexate resistance in osteosarcoma cells through miR-200a-3p/O-GlcNAc transferase pathway.
Sun MX; An HY; Sun YB; Sun YB; Bai B
J Orthop Surg Res; 2022 Dec; 17(1):557. PubMed ID: 36544170
[TBL] [Abstract][Full Text] [Related]
13. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
15. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer.
Pan JX; Qu F; Wang FF; Xu J; Mu LS; Ye LY; Li JJ
Arch Gynecol Obstet; 2017 Dec; 296(6):1145-1152. PubMed ID: 28975405
[TBL] [Abstract][Full Text] [Related]
16. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
17. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
Lilienthal I; Herold N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961800
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.
Cheng M; Duan PG; Gao ZZ; Dai M
Oncol Rep; 2020 Dec; 44(6):2691-2700. PubMed ID: 33125503
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential chemoresistance genes in osteosarcoma.
Walters DK; Steinmann P; Langsam B; Schmutz S; Born W; Fuchs B
Anticancer Res; 2008; 28(2A):673-9. PubMed ID: 18507006
[TBL] [Abstract][Full Text] [Related]
20. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.
Li C; Cai J; Ge F; Wang G
Int J Mol Med; 2018 Oct; 42(4):1799-1808. PubMed ID: 30015899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
